journal cover

Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections

Antimicrobial Agents and Chemotherapy

Jan 15, 2020

Sarah C J JorgensenMichael J Rybak

Abstract

Objective: To describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) gram-negative infections.Methods: Multicenter, retrospective, cohort study at eight U.S. medical centers (2015-201...read more

Mentioned in this Paper

Follow-up
Multicenter Study
Drug Resistance
Experience
Population Group
Clinical Failure
Acute Kidney Injury
Respiratory System
Clostridium difficile (bacteria)
Kidney
9
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Vitamin K Carboxylase & Antibiotics

Vitamin K-dependent carboxylases generate gamma-carboxyglutamic acids with malonate moieties by modifying glutamate residues in vitamin K-dependent proteins. This feed focuses on cellular mechanisms regulated by vitamin K-dependent carboxylases.

Clostridium Difficile Infection

Clostridium difficile infection (CDI) is the leading cause of infectious diarrhoea in hospitalised patients. Discover the latest research on CDI here.

Drug-Resistant Infections

Drug resistant infections are one of the biggest threats in our public health care system. Discover the latest research here.

© 2020 Meta ULC. All rights reserved

Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections

Antimicrobial Agents and Chemotherapy

Jan 15, 2020

Sarah C J JorgensenMichael J Rybak

PMID: 31932379

DOI: 10.1128/aac.02291-19

Abstract

Objective: To describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) gram-negative infections.Methods: Multicenter, retrospective, cohort study at eight U.S. medical centers (2015-201...read more

Mentioned in this Paper

Follow-up
Multicenter Study
Drug Resistance
Experience
Population Group
Clinical Failure
Acute Kidney Injury
Respiratory System
Clostridium difficile (bacteria)
Kidney
9

Similar Papers Found In These Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Vitamin K Carboxylase & Antibiotics

Vitamin K-dependent carboxylases generate gamma-carboxyglutamic acids with malonate moieties by modifying glutamate residues in vitamin K-dependent proteins. This feed focuses on cellular mechanisms regulated by vitamin K-dependent carboxylases.

Related Papers

Open Forum Infectious Diseases

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections

Open Forum Infectious DiseasesJanuary 1, 2020
Sarah C J JorgensenMichael J Rybak
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/real-world-experience-with-ceftolozane-tazobactam/31932379